The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

PT-141

FDA-approved · Grade B

Goals
libido
Evidence
4 RCT / 0 animal / 0 in vitro
Routes
injectable-sc, nasal
WADA
No
FDA
Approved
Cancer caution
none
Typical dose
—
Half-life
These structural features give bremelanotide a plasma half-life of approximately 1-2 hours after SubQ injection — longer than most linear peptides.
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Enclomiphene

Off-label · Grade C

Goals
hormonal, libido, muscle
Evidence
4 RCT / 1 animal / 2 in vitro
Routes
oral
WADA
S4
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
short plasma half-life (estimated ~10-12 hours in humans under repeated dosing)
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Gonadorelin

FDA-approved · Grade C

Goals
hormonal, libido
Evidence
—
Routes
injectable-sc
WADA
No
FDA
Approved
Cancer caution
none
Typical dose
—
Half-life
The 2-4 minute plasma half-life means that any gonadorelin injection is a brief pulse that clears within minutes
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Human Chorionic Gonadotropin

FDA-approved · Grade B

Goals
hormonal, libido, muscle
Evidence
14 RCT / 0 animal / 0 in vitro
Routes
injectable-sc, injectable-im
WADA
S2
FDA
Approved
Cancer caution
hard-stop
Typical dose
—
Half-life
The 36-hour half-life of hCG vs LH's 30 minutes reflects the CTP extension's protective effect against renal clearance and plasma peptidase degradation
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →